Sotagliflozin: Side Effects, Uses & Monitoring
INPEFA is indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with: heart failure or type 2 diabetes mellitus, chronic kidney disease, and oth
- Data source
- FDA labeling via NIH DailyMed (label 1a46614e…)
- Label version
- current
- Last reviewed
- 2026
Reported adverse reactions
Reactions listed in current FDA labeling, with the highest frequency reported across summarized placebo-controlled trials.
No structured frequency data available in current labeling. Consult the official label.
Labeled uses (from FDA prescribing information)
INPEFA is indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with: heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors
Conditions associated with Sotagliflozin in labeling
Chronic Kidney Disease
Progressive loss of kidney function over time, often caused by diabetes and hypertension, leading to buildup o...
Heart Failure
A condition in which the heart cannot pump blood effectively, leading to fluid buildup in the lungs and body a...
Type 2 Diabetes
A chronic condition in which the body becomes resistant to insulin or does not produce enough insulin to maint...
Frequently Asked Questions
What is Sotagliflozin used for?
FDA labeling lists the approved uses shown above under "Labeled uses." This summary is informational; only a qualified prescriber can determine whether a medication is appropriate for you.
What are the most commonly reported side effects of Sotagliflozin?
Current labeling for this ingredient does not include a structured frequency table that we can reproduce. Review the official label linked below.
Does Sotagliflozin require lab monitoring?
Monitoring needs vary. Ask your healthcare provider whether any lab tests apply while taking Sotagliflozin.
Where does this information come from?
All clinical facts on this page were extracted from the current FDA-registered product labeling for this ingredient, published by manufacturers through NIH DailyMed. See the source link below.
Medical disclaimer: Educational content extracted from public FDA labeling. Not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.